检索结果-南通市图书馆

Screening of novel synthetic derivatives of dehydroepiandrosterone for Antivirals against flaviviruses infections

Virologica Sinica 2022年第1期37卷 94-106页

作者： Muhammad Imran Luping Zhang Bohan Zheng Zikai Zhao Dengyuan Zhou Shengfeng Wan Zheng Chen Hongyu Duan Qiuyan Li Xueqin Liu Shengbo Cao Shaoyong Ke Jing Ye State Key Laboratory of Agricultural Microbiology Huazhong Agricultural UniversityWuhan430070China Key Laboratory of Preventive Veterinary Medicine in Hubei Province College of Veterinary MedicineHuazhong Agricultural UniversityWuhan430070China The Cooperative Innovation Center for Sustainable Pig Production Huazhong Agricultural UniversityWuhan430070China Department of Pathology Faculty of Veterinary ScienceUniversity of AgricultureFaisalabad38040Pakistan Department of Nephrology Henan Provincial Key Laboratory of Kidney Diseases and ImmunologyHenan Provincial People's HospitalZhengzhou450003China Key Laboratory for Animal Health of Jiangxi Province Nanchang330045China Department of Preventive Veterinary Medicine College of Animal Science and TechnologyJiangxi Agricultural UniversityNanchang330045China College of Fisheries Huazhong Agricultural UniversityWuhan430070China National Biopesticide Engineering Research Center Hubei Biopesticide Engineering Research CenterHubei Academy of Agricultural SciencesWuhan430070China

Flaviviruses are important arthropod-borne pathogens that represent an immense global health problem.Their unprecedented epidemic rate and unpredictable clinical features underscore an urgent need for antiviral interventions.Dehydroepiandrosterone(DHEA)is a natural occurring adrenal-derived steroid in the human body that has been associated in protection against various infections.In the present study,the plaque assay based primary screening was conducted on 32 synthetic derivatives of DHEA against Japanese encephalitis virus(JEV)to identify potent anti-flaviviral compounds.Based on primary screening,HAAS-AV3026 and HAAS-AV3027 were selected as hits from DHEA derivatives that exhibited strong antiviral activity against JEV(IC_(50)=2.13 and 1.98μmol/L,respectively)and Zika virus(ZIKV)(IC_(50)=3.73 and 3.42μmol/L,respectively).Mechanism study indicates that HAAS-AV3026 and HAAS-AV3027 do not exhibit inhibitory effect on flavivirus binding and entry process,while significantly inhibit flavivirus infection at the replication stage.Moreover,indirect immunofluorescence assay,Western blot analyses,and quantitative reverse transcription-PCR(qRT-PCR)revealed a potent antiviral activity of DHEA derivatives hits against JEV and ZIKV in terms of inhibition of viral infection,protein production,and viral RNA synthesis in Vero cells.Taken together,our results may provide a basis for the development of new Antivirals against flaviviruses.

关键词： Flaviviruses Japanese encephalitis virus(JEV) Zika virus(ZIKV) Dehydroepiandrosterone(DHEA) Antivirals

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting Antivirals

引用

World Journal of Gastroenterology 2018年第11期24卷 1269-1277页

作者： Mazen Noureddin Micaela M Wong Tsuyoshi Todo Shelly C Lu Arun J Sanyal Edward A Mena Fatty Liver Program Cedars-Sinai Medical CenterLos AngelesCA 90048United States Division of Digestive and Liver Diseases Cedars-Sinai Medical CenterLos AngelesCA 90048United States California Liver Research Institute PasadenaCA 91105United States Comprehensive Transplant Center Department of SurgeryCedars-Sinai Medical CenterLos AngelesCA 90048United States Division of Digestive and Liver Diseases Cedars-Sinai Medical CenterLos AngelesCA 90048United States Division of Gastroenterology Hepatology and NutritionDepartment of Internal MedicineSchool of MedicineVirginia Commonwealth UniversityRichmondVA 23298United States

AIM To determine steatosis and fibrosis prevalence in hepatitis C patients after a sustained virological response achieved with direct-acting Antivirals.METHODS Transient elastography with controlled attenuation parameter(CAP) was used to assess hepatic steatosis post-sustained virological response(SVR);the CAP technology was not available in the United States at study initiation.Liver stiffness/fibrosis was measured before and 47 wk after treatment completion.Patients with genotype 3 and patients with cirrhosis were excluded.RESULTS One hundred and one patients were included in the study.Post-SVR there were decreases from baseline in alanine aminotransferase(ALT)(63.1 to 17.8 U/L),aspartate aminotransferase(51.8 to 21.5 U/L) and fibrosis score(7.4 to 6.1 k Pa)(P < 0.05).Post-SVR,48 patients(47.5%) had steatosis on CAP;of these,6.25% had advanced fibrosis.Patients with steatosis had higher body mass index(29.0 vs 26.1 kg/m2),glucose(107.8 vs 96.6 mg/d L),ALT(20.4 vs 15.3 mg/d L),CAP score(296.3 vs 212.4 d B/m) and fibrosis score(7.0 vs 5.3 k Pa);P < 0.05.Interestingly,compared to baseline,both patients with and without steatosis had change in fibrosis score post-SVR(7.7 k Pa vs 7.0 k Pa and 7.0 k Pa vs 5.3 k Pa);alternatively,(P < 0.05) and therefore patients with steatosis continued to have clinically significant stiffness(≥ 7 k Pa).CONCLUSION Fatty liver is very common in hepatitis C virus(HCV) patients post-SVR.These patients continue to have elevated mean fibrosis score(≥ 7 k Pa) compared to those without fatty liver;some have advanced fibrosis.Long term follow up is needed to assess steatosis and fibrosis in HCV patients post-SVR.

关键词： Nonalcoholic fatty liver disease Hepatitis C Fibrosis Steatosis Sustained virological response Direct-acting Antivirals

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Metabolic syndrome does not affect sustained virologic response of direct-acting Antivirals while hepatitis C clearance improves hemoglobin A1c

引用

World Journal of Hepatology 2018年第9期10卷 612-621页

作者： Tien S Dong Elizabeth S Aby Jihane N Benhammou Jenna Kawamoto Steven-Huy Han Folasade P May Joseph R Pisegna the Vatche and Tamar Manoukian Division of Digestive Diseases University of California Los AngelesDepartment of MedicineUniversity of California David Geffen School of MedicineLos AngelesCA 90095United States Division of Gastroenterology Hepatology and Parenteral NutritionDepartment of MedicineVA Greater Los Angeles Healthcare SystemLos AngelesCA 90073United States the Pfleger Liver Institute Department of SurgeryUniversity of California David Geffen School of MedicineLos AngelesCA 90095United States VA Health Services Research and Development Center for the Study of Healthcare Innovation Center for the Study of Healthcare Innovation Implementation and Policy(CSHIIP)Los AngelesCA 90073United States Jonsson Comprehensive Cancer Center Los AngelesCA 90095United States

AIM To determine whether successful treatment with direc-tacting Antivirals(DAA) is associated with improvements in hemoglobin A1 c(HbA1 c) and if type 2 diabetes mellitus(T2 DM) or metabolic syndrome affects sustained virologic response(SVR).METHODS We performed a retrospective analysis of all hepatitis C virus(HCV) patients at the VA Greater Los Angeles Healthcare System treated with varying DAA therapy between 2014-2016. Separate multivariable logistic regression was performed to determine predictors of HbA1 c decrease ≥ 0.5 after DAA treatment and predictors of SVR 12-wk post treatment(SVR12).RESULTS A total of 1068 patients were treated with DAA therapy between 2014-2016. The presence of T2 DM or metabolic syndrome did not adversely affect SVR12. 106 patients had both HCV and T2 DM. Within that cohort,patients who achieved SVR12 had lower mean HbA1 c pre treatment(7.35 vs 8.60,P = 0.02),and lower mean HbA1 c post-treatment compared to non-responders(6.55 vs 8.61,P = 0.01). The mean reduction in HbA1 c after treatment was greater for those who achieved SVR12 than for non-responders(0.79 vs 0.01,P = 0.03). In adjusted models,patients that achieved SVR12 were more likely to have a HbA1 c decrease of ≥ 0.5 than those that did not achieve SVR12(adjusted OR = 7.24,95%CI: 1.22-42.94). CONCLUSION In HCV patients with T2 DM,successful treatment with DAA was associated with a significant reduction in HbA1 c suggesting that DAA may have a role in improving insulin sensitivity. Furthermore,the presence of T2 DM or metabolic syndrome does not adversely affect SVR12 rates in patients treated with DAA.

关键词： Hepatitis C virus Hemoglobin A1c Diabetes mellitus Direct-acting Antivirals Metabolic syndrome

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Theory and reality of Antivirals against SARS-CoV-2

引用

World Journal of Clinical Cases 2021年第23期9卷 6663-6673页

作者： Bo Zhao Teng-Fei Yang Rui Zheng Department of Pulmonary and Critical Care Medicine Shengjing Hospital of China Medical UniversityShenyang 110004Liaoning ProvinceChina Department of Health Management and Family Medicine Shengjing Hospital of China Medical UniversityShenyang 110004Liaoning ProvinceChina

At present,over 180 million people have been infected with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)worldwide and there have been more than 3.8 million deaths due to the virus.However,specific effective antiviral treatment for this infectious disease is absent.At the beginning of the epidemic,relevant cellular and animal experiments of antiviral treatment for SARS-CoV-2 were conducted based on the prior studies of SARS-CoV and Middle East respiratory syndrome coronavirus.Some Antivirals were preliminarily validated to be potentially effective in the clinical settings.But as the epidemic continued and more studies were carried out,the efficacy of these antiviral drugs became controversial.This paper reviews the pharmacology and application of interferon,lopinavir/ritonavir,ribavirin,chloroquine,arbidol,favipiravir,remdesivir,and thymosinα1 in coronavirus disease 2019.The actual effect of these drugs remains controversial.Meanwhile,the efficacy and safety of these drugs for patients with coronavirus disease 2019 still need to be explored.

关键词： SARS-CoV-2 Antivirals Efficacy Safety Middle East respiratory syndrome coronavirus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Impact of direct acting Antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

引用

World Journal of Hepatology 2018年第2期10卷 267-276页

作者： Amna Subhan Butt Fatima Sharif Shahab Abid Section of Gastroenterology Department of Medicine Aga Khan University Hospital

Hepatocellular carcinoma(HCC) is a major cause of morbidity and mortality worldwide. Chronic hepatitis C virus infection(HCV) is the most common cause of HCC in many European countries, Japan and Pakistan. Introduction of the new direct acting Antivirals(DAAs) has revolutionized the management of HCV worldwide, with high rates of sustained virologic response in patients who could not have tolerated the previous interferon based treatments. However, recently there have been reports raising caution about the long term effects of DAAs, particularly a possible increased risk of HCC. Therefore this review explores the current molecular studies as well as clinical data that investigate the impact of DAAs on occurrence and recurrence of HCC.

关键词： Hepatocellular carcinoma Direct acting Antivirals Hepatitis C

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Treatment of chronic hepatitis C with direct-acting Antivirals: The role of resistance

引用

World Journal of Gastroenterology 2016年第29期22卷 6573-6581页

作者： Miguel Jiménez-Pérez Rocío González-Grande Pilar Espana Contreras Isabel Pinazo Martínez Jesús de la Cruz Lombardo Raúl Olmedo Martín UGC de Aparato Digestivo Unidad de Hepatologia-Trasplante Hepatico Hospital Universitario Regional de Malaga 29010 Malaga Spain Liver transplantation and hepatology unit UGC de Aparato Digestivo Hospital Regional Universitario 29010 Malaga Spain

The use of direct-acting Antivirals(DAAs) to treat chronic hepatitis C has resulted in a significant increase in rates of sustained viral response(around 90%-95%) as compared with the standard treatment of peginterferon/ribavirin. Despite this, however, the rates of therapeutic failure in daily clinical practice range from 10%-15%. Most of these cases are due to the presence of resistant viral variants, resulting from mutations produced by substitutions of amino acids in the viral target protein that reduce viral sensitivity to DAAs, thus limiting the efficacy of these drugs. The high genetic diversity of hepatitis C virus has resulted in the existence of resistance-associated variants(RAVs), sometimes even before starting treatment with DAAs, though generally at low levels. These preexisting RAVs do not appear to impact on the sustained viral response, whereas those that appear after DAA therapy could well be determinant in virological failure with future treatments. As well as the presence of RAVs, virological failure to treatment with DAAs is generally associated with other factors related with a poor response, such as the degree of fibrosis, the response to previous therapy, the viral load or the viral genotype. Nonetheless, viral breakthrough and relapse can still occur in the absence of detectable RAVs and after the use of highly effective DAAs, so that the true clinical impact of the presence of RAVs in therapeutic failure remains to be determined.

关键词： Direct-acting Antivirals Resistance Treatment Hepatitis C virus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Era of direct acting Antivirals in chronic hepatitis C: Who will benefit?

引用

World Journal of Hepatology 2015年第24期7卷 2543-2550页

作者： James Fung Department of Medicine Queen Mary Hospitalthe University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver Research the University of Hong Kong

In the era of highly effective direct acting antiviral(DAA) drugs for the treatment of chronic hepatitis C(CHC) infection, where eradication is almost ensured with minimal side effects, all hepatitis C carriers should benefit theoretically. In the real world setting however, only a small proportion will benefit at this time point due to the multiple barriers to accessing therapy. Given that universal treatment is unlikely, treatment with DAAs will likely be restricted to those with the highest health benefits, and for those who can afford the high expense of a treatment course. Those with the highest unmet needs include those who have failed previous interferon-based therapy or who are interferon-ineligible with evidence of active disease, those with advance liver disease, and those with recurrence of hepatitis C after liver transplantation. In the future, the focus should be on increasing access to treatment for those infected with CHC.

关键词： Treatment Direct acting Antivirals Benefit Unmet n

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Update on hepatitis C: Direct-acting Antivirals

引用

World Journal of Hepatology 2015年第28期7卷 2829-2833页

作者： Leon L Seifert Ryan B Perumpail Aijaz Ahmed Department of Transplantation Medicine University Hospital Münster Division of Gastroenterology and Hepatology Stanford University School of Medicine

Hepatitis C virus(HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting Antivirals(DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.

关键词： Hepatitis C virus Direct-acting Antivirals Sustained virologic response Management Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Predictors of Direct-Acting Antivirals Failure in Patients with Chronic Hepatitis C Virus in Ivory Coast: About 5 Cases

引用

Open Journal of Gastroenterology 2019年第10期9卷 193-201页

作者： Dimitri Hatrydt Kouamé Stanislas Adjéka Doffou Henriette Kissi Anzouan-Kacou Yannick Mfupa Tchana Aboubakar Demba Bangoura Mahassadi Kouamé Alassan Fulgence Bathaix Yao Alain Koffi Attia Thérè se Ndri Yoman Hepatogastroenterology Unit Yopougon Teaching Hospital Yopougon C&ocirc te d’Ivoire

Context and Aim: Direct-acting Antivirals are the therapeutic revolution in the management of viral hepatitis C, but often with a few cases of failure. The aim of this study was to identify factors that may be implicated in the failure of direct-acting antiviral therapy in patients with hepatitis C virus in Ivory Coast. Methodology: This was a cross-sectional and descriptive study with a retrospective compendium of data from the year 2016 to the year 2018. This study included all patients with chronic viral hepatitis C, patients naive to antiviral treatment, or pre-treated patients in whom a failure to treatment with direct-acting antiviral has been diagnosed. Results: During the study period, 5 patients out of 14 cases of therapeutic failure were included, i.e. 35.71%. Most of the patients were over 50 years (4 out of 5) and predominantly female (3 out of 5). High blood pressure was the most common comorbidity (3 out of 5 patients). Genotype 1 was found in 4 patients versus 1 case of genotype 2. None of the patients had hepatitis B or HIV coinfection. A viral load > 6log was found in 4 patients at baseline. All our patients had hepatic cytolysis. Two of them were cirrhotic. All 4 cases of genotype 1 benefited from the combination sofosbuvir + ledipasvir for 12 weeks and the case of genotype 2 from the combination sofosbuvir + ribavirin for 24 weeks. The resistance mutations were observed mainly on the sequencing of NS5A at the Y93H, L31M, 28L, 30T, 31V, 58S and 93H genes and a case of mutation on the N3 gene sequencing. Conclusion: Age > 50 years, comorbidities (high blood pressure), polymedication, female gender, genotype 1b, viremia > 6log, and cytolysis were the profile of patients with treatment of HCV by direct-acting antiviral failure.

关键词： HVC Direct-Acting Antivirals Failure Ivory Coast

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effectiveness of Treatment of Chronic Viral Hepatitis C by Direct-Acting Antivirals in Togo

引用

Open Journal of Gastroenterology 2019年第7期9卷 125-133页

作者： Laté Mawuli Lawson-Ananissoh Aklesso Bagny Oumboma Bouglouga Laconi Kaaga Rafiou El-Hadji Yakoubou Lidaw Kogoe Datouda Redah Hepatogastroenterology Unit University Hospital Campus Lomé Togo Hepatogastroenterology Unit University Hospital of Kara Kara Togo

Background: Viral hepatitis C is the second leading cause of hepatocellular carcinoma after hepatitis B in Africa and Togo in particular. The advent of direct acting Antivirals has revolutionized the care and prognosis of patients infected with hepatitis C virus (HCV). Objective: To evaluate the sustained virological response (SVR) 12 weeks after oral treatment without interferon in HCV infected patients with genotypes 1 and 2. Patients and Method: Descriptive and analytical study based on the retrospective collection of data in the hepatogastroenterology unit of the University Hospital Campus of Lome (Togo) from July 11, 2016 to April 22, 2018. All patients who had a chronic viral hepatitis C with viral replication, naive, regardless of the genotype, regardless of the degree of liver fibrosis, and who had completed their treatment with direct-acting Antivirals were included. Results: We recruited 84 patients, 60 of whom were infected with HCV genotype 2 (71.43%) and 24 with HCV genotype 1 (28.57%). There were 58 men and 26 women (sex ratio: 0.45). In HCV genotype 1 patients, the median age was 54.29 years and Sofosbuvir/Ledipasvir was the most used combination (62.50%). In HCV genotype 2 patients, the median age was 54.5 years and Sofosbuvir associated with Ribavirin was the most used treatment (81.66%). The virological response at the end of treatment was 100% (genotype 1) and 93.30% (genotype 2). The SVR 12 was 100% (genotype 1) and 91.70% (genotype 2). Five patients were in treatment failure (genotype 2). Conclusion: Direct-acting Antivirals were effective in our patients. The rate of sustained virological response was above 90%.

关键词： Viral Hepatitis C Direct-Acting Antivirals Sustained Virological Response Togo

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：